Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Guided TherapeuticsGTHP 22 3-Year EBITDA Growth Rate is 34.30% as of Mar. 2026, which is 30% above its 10-year median of 26.45. GuruFocus rates GTHP with a GF Score™ of 22/100. The stock has 4 warning signs investors should review. Among 692 Medical Devices & Instruments companies, Guided Therapeutics ranks better than 80.49% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 34.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Guided Therapeutics was 94.40% per year. The lowest was 8.60% per year. And the median was 26.45% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Guided Therapeutics 3-Year EBITDA Growth Rate Related Terms
GTHP vs PETV, FOFA, CTSO: 3-Year EBITDA Growth Rate Comparison
For the Medical Devices subindustry, Guided Therapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Guided Therapeutics 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Guided Therapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Guided Therapeutics's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 34.30% mean?
Guided Therapeutics (GTHP) has a 3-Year EBITDA Growth Rate of 34.30% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Guided Therapeutics and its competitors. This is 30% above median its historical median of 26.45. Over the past decade, Guided Therapeutics' 3-Year EBITDA Growth Rate has ranged from 8.60 to 94.40. According to the industry distribution chart, Guided Therapeutics ranks #135 out of 692 companies in the Medical Devices & Instruments industry, placing it in the top 19.5%.
Is Guided Therapeutics' 3-Year EBITDA Growth Rate too high?
Guided Therapeutics' current 3-Year EBITDA Growth Rate of 34.30% is 30% above median its 10-year median of 26.45. Over the past 10 years, this metric has ranged from a low of 8.60 to a high of 94.40. The Medical Devices & Instruments industry median 3-Year EBITDA Growth Rate is 8.20. Guided Therapeutics' value of 34.30% is 318.3% above this industry median. Based on the distribution chart, Guided Therapeutics ranks #135 out of 692 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Guided Therapeutics has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Guided Therapeutics' 3-Year EBITDA Growth Rate compare to PETV and FOFA?
According to the Medical Devices & Instruments industry distribution chart, Guided Therapeutics ranks #135 out of 692 companies for 3-Year EBITDA Growth Rate. This places Guided Therapeutics in the top 20% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 8.20. Guided Therapeutics' value of 34.30% is 318.3% above this benchmark. Historically, Guided Therapeutics' own 3-Year EBITDA Growth Rate has ranged from 8.60 to 94.40 over the past decade. While the company's 10-year median is 26.45 vs. the industry median of 8.20, Guided Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 8.20, based on 692 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Guided Therapeutics's current 3-Year EBITDA Growth Rate of 34.30% is 318.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Guided Therapeutics and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 8.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Guided Therapeutics's current 3-Year EBITDA Growth Rate is 34.30%, which is 30% above median its own 10-year median of 26.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guided Therapeutics stock overvalued right now?
Guided Therapeutics (GTHP) has a current 3-Year EBITDA Growth Rate of 34.30%. The current 3-Year EBITDA Growth Rate is 34.30%, which is 30% above median its 10-year median of 26.45 and 318.3% above the Medical Devices & Instruments industry median of 8.20. Guided Therapeutics' overall GF Score™ is 22/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Guided Therapeutics (GTHP), the current 3-Year EBITDA Growth Rate is 34.30% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Guided Therapeutics Inc is a medical technology company. It is engaged in developing medical devices that have the potential to improve healthcare. Its primary focus is the sales and marketing of its LuViva Advanced Cervical Scan non-invasive cervical cancer detection device and the extension of its cancer detection technology into other cancers, including esophageal. The company generates revenue from the sale of medical devices.
22GF Score
Get the complete analysis for GTHP
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GTHP has been successfully added to your 
